foxo4-dri senolytic 2023 Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis Frontiers | FOXO4-DRI regulates endothelial
Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $7.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



